FBN1

Details of the Concept

FBN1 is the gene encoding fibrillin-1, located on chromosome 15q21.1. Fibrillin-1 is a 350 kDa glycoprotein that is the principal component of extracellular matrix microfibrils, present in all tissues with phenotypic manifestations of Marfan syndrome (MFS). Loss-of-function mutations in FBN1 are the predominant (and likely sole) cause of classic Marfan syndrome. Over 1,500 mutations have been described (as of 2015; was >1,000 as of 2010); the vast majority are private (unique to individual families). The gene contains 65 exons spanning 235 kb of genomic DNA.

Key Facts

• Chromosomal location: 15q21.1; linked to MFS in 1990 sources/marfan-lancet-2005 (high)
• Gene structure: 65 exons, 235 kb genomic DNA; encodes a 350 kDa glycoprotein highly conserved across species sources/marfan-lancet-2005 (high)
• Mutation spectrum: >1,500 mutations described (as of 2015; was >1,000 in 2010; >500 in 2005); >90% are private (family-specific); most missense mutations alter a single amino acid out of 2,871 aa, mainly in EGF-like domains, disrupting cysteine residues (disulfide bonds → domain folding) or residues affecting calcium binding → enhanced proteolytic degradation sources/marfan-lancet-2005 (high) sources/marfan-naturerc-2010 (medium) sources/marfan-ghent-aclingene-2015 (high)
• Variants of uncertain significance (VUS): An increasing proportion of FBN1 nucleotide variants have uncertain clinical significance — a growing source of diagnostic uncertainty as sequencing has expanded; no standardised approach to VUS reclassification in MFS currently established sources/marfan-ghent-aclingene-2015 (high)
• Exon 24–32 genotype–phenotype correlation: mutations in exons 24–32 predict more severe phenotype; neonatal Marfan syndrome (most severe form) almost exclusively maps to this region sources/marfan-naturerc-2010 (medium)
• Molecular mechanism: Haploinsufficiency is the critical threshold mechanism; dominant-negative effect of mutant protein is contributory but insufficient alone. Transgenic overexpression of mutant FBN1 with 2 normal alleles does not cause vascular disease; adding wild-type allele to heterozygous missense mice rescues the aortic phenotype sources/marfan-lancet-2005 (high)
• Function beyond structure: Fibrillin-1-rich microfibrils sequester latent TGF-β complexes in the ECM; deficiency → excess free TGF-β signalling. This is now understood as a central mechanism for most non-lens Marfan manifestations sources/marfan-lancet-2005 (high)
• Homology: FBN1 shares high homology with latent TGF-β binding proteins (LTBPs); this structural similarity underlies its cytokine regulatory role sources/marfan-lancet-2005 (high)
• Postnatal role: Fibrillin-1 microfibrils are required to maintain (not initially assemble) elastic fibres during postnatal life; deficiency leads to vascular smooth-muscle cell activation, MMP-2/9 upregulation, elastic fibre calcification, and vascular wall collapse sources/marfan-lancet-2005 (high)
• Genotype-phenotype: Minimal correlation; same mutation → variable phenotype even within families; phenotypic severity may correlate inversely with expression level of the normal (non-mutant) allele sources/marfan-lancet-2005 (high)
• RGD integrin-binding sequence: Fibrillin-1 contains a single integrin-binding Arg-Gly-Asp (RGD) sequence; mutations in this domain cause Stiff Skin Syndrome (SSS) — a congenital scleroderma characterised by severe dermal fibrosis, joint contracture, and short stature sources/marfan-cv-clingene-2015 (high)
• Force-transmitting role: Fibrillin-1 functions as a force-transmitting molecule in the myocardium; deficiency leads to impaired cardiomyocyte mechanosignaling and primary DCM independent of valvular disease (Cook 2014 JCI) sources/marfan-cv-clingene-2015 (high)
• Circulating fibrillin-1 fragments as biomarkers: Circulating fibrillin-1 fragment concentrations are associated with TAA frequency and dissection; under development as a biomarker to complement aortic diameter measurements (Marshall 2013 Circ Res) sources/marfan-cv-clingene-2015 (high)
• Other fibrillinopathies: FBN1 mutations also cause MASS phenotype, familial mitral valve prolapse syndrome, familial ectopia lentis, isolated Marfanoid habitus, Weill-Marchesani syndrome (WMS), Stiff Skin Syndrome (SSS), acromicric dysplasia, and geleophysic dysplasia (AD) sources/marfan-lancet-2005 (high) sources/marfan-cv-clingene-2015 (high)
• Locus heterogeneity: WMS and acromiclic dysplasias can also result from ADAMTSL2 and ADAMTS10 mutations (which bind fibrillin-1 in vitro); Shprintzen-Goldberg syndrome is now attributed to SKI mutations (not FBN1) sources/marfan-lancet-2005 (high) sources/marfan-cv-clingene-2015 (high)
• Genetic testing limitations: ~10% of classic MFS mutations missed by conventional screening; gene testing lacks both sensitivity and specificity for clinical diagnosis sources/marfan-lancet-2005 (high)

Contradictions / Open Questions

• Dominant-negative vs haploinsufficiency debate: Authors favour haploinsufficiency as critical mechanism based on mouse model data; however the contribution of dominant-negative effects remains a subject of ongoing investigation
• VUS burden: The increasing proportion of FBN1 variants of uncertain significance reduces diagnostic certainty in MFS; no standardised reclassification protocol established — a growing challenge as genetic testing expands sources/marfan-ghent-aclingene-2015 (high)
• Boosting fibrillin-1 expression as therapeutic strategy is theoretically attractive (supported by genetic modifier data showing severity inversely related to normal allele expression level), but no clinical approach has been developed

Connections

• Related to concepts/Marfan-Syndrome — primary disease caused by FBN1 mutations
• Related to entities/Loeys-Dietz-Syndrome — Loeys-Dietz caused by TGFBR1/TGFBR2 mutations, sharing the same downstream TGF-β pathway dysregulation as FBN1 deficiency

Sources

• sources/marfan-lancet-2005 (high)
• sources/marfan-naturerc-2010 (medium)
• sources/marfan-cv-clingene-2015 (high)
• sources/marfan-ghent-aclingene-2015 (high)